Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer by Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, De Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, De Bono, JS, Banerji, U

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (K... by Le Bihan, Y-V, Lanigan, RM, Atrash, B, McLaughlin, MG, Velupillai, S, Malcolm, AG, England, KS, Ruda, GF, Mok, NY, Tumber, A, Tomlin, K, Saville, H, Shehu, E, McAndrew, C, Carmichael, L, Bennett, JM, Jeganathan, F, Eve, P, Donovan, A, Hayes, A, Wood, F, Raynaud, FI, Fedorov, O, Brennan, PE, Burke, R, Van Montfort, RLM, Rossanese, OW, Blagg, J, Bavetsias, V